Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1469

Shown on this page

Current sort

Stored official records

Conditions: B-Cell, B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Lenalidomide, Obinutuzumab, Venetoclax; Drug · Biological
Lead sponsor: Beth Christian; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Classical Hodgkin Lymphoma
Interventions: Ibrutinib, Laboratory Biomarker Analysis, Nivolumab; Drug · Other · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Environmental Exposure
Interventions: Centrum, Cholestyramine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HCC
Interventions: Electroporation Device, GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, INO-9012; Device · Biological
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: HIV -1 Infection
Interventions: GS-0415, GS-0415 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mRNA-2808; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Noonan Syndrome
Interventions: Vosoritide Injection; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 18 more

Conditions: Complex Coronary Artery Disease, Coronary Artery Disease, Coronary Artery Disease Risk High
Interventions: IVUS; Device
Lead sponsor: ECRI bv; Industry
Eligibility: 18 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Coral Gables, Florida + 12 more

Conditions: Metastatic Colorectal Cancer
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 20 more

Conditions: Lung Transplant Rejection
Interventions: Azithromycin, Belumosudil, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: CNS Tumors, Solid Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: HIV Infections
Interventions: Health MPowerment App; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

About this Emory University (Winship Cancer Institute) institution page

What this page lists: ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Emory University (Winship Cancer Institute)

Filter and sort this campus

Stored official records

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

PFAS Clinical Trial

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Study of GS-0415 and How It Works in People With HIV

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

IVUS CHIP UPP Registry

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta

About this Emory University (Winship Cancer Institute) institution page